GCP
NWBO

GSA Capital Partners’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

GSA Capital Partners’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-40,825
Closed -$22K – 2157
2016
Q3 		$22K Buy
40,825
+26,086
+177% +$11.9K ﹤0.01% 1731
2016
Q2 		$9K Buy
+14,739
New +$15.7K ﹤0.01% 1705

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

GSA Capital Partners's NWBO Position: Q4 2016 in Review

GSA Capital Partners sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 40,825 shares — an estimated $22K sold.

GSA Capital Partners first reported a position in NWBO in Q2 2016 and held it in 2 quarters. The position peaked at $22K in Q3 2016. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • GSA Capital Partners reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • GSA Capital Partners sold 40,825 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $22K.
  • GSA Capital Partners first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2016 and held it in 2 quarters.
  • GSA Capital Partners's Northwest Biotherapeutics, Inc. Common stock position peaked at $22K in Q3 2016.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on GSA Capital Partners's 13F filing for Q4 2016, filed 14 Feb 2017.